Nephrology

This symposium at ERA 2025 explored the evolving treatment landscape in immunoglobulin A nephropathy (IgAN) and novel, targeted therapies…

IgA nephropathy (IgAN) can impact life expectancy in those affected, thus efficacious treatment is key. Endothelin 1 (ET-1) and angiotensin…

Advances in Therapy to Address Proteinuria in Patients with Immunoglobulin A Nephropathy. As the majority of patients with IgA…

IgAN is an immune-complex mediated glomerular disease with an incidence rate of 0.03−10.5/100,000 persons/year…

In patients with immunoglobulin A nephropathy, use of the endothelin 1 Type A/Ang II subtype 1 receptor antagonist sparsentan can decrease proteinuria and preserve kidney function

IgAN, which can lead to CKD and kidney failure, is the most common form of primary glomerulonephritis, predominantly…

This article was funded by Sanofi and is intended for healthcare professionals.

Bengt Fellström, Uppsala University, Sweden, described the relationship between IgA nephropathy (IgAN) and gastrointestinal mucosal…